{
  "DOI": "10.1038/s41431-020-0638-4",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-020-0638-4",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eFifty years after the recognition of the Li–Fraumeni syndrome (LFS), our perception of cancers related to germline alterations of \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e has drastically changed: (i) germline \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e alterations are often identified among children with cancers, in particular soft-tissue sarcomas, adrenocortical carcinomas, central nervous system tumours, or among adult females with early breast cancers, without familial history. This justifies the expansion of the LFS concept to a wider cancer predisposition syndrome designated heritable \u003cjats:italic\u003eTP53-\u003c/jats:italic\u003erelated cancer (h\u003cjats:italic\u003eTP53\u003c/jats:italic\u003erc) syndrome; (ii) the interpretation of germline \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e variants remains challenging and should integrate epidemiological, phenotypical, bioinformatics prediction, and functional data; (iii) the penetrance of germline disease-causing \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e variants is variable, depending both on the type of variant (dominant-negative variants being associated with a higher cancer risk) and on modifying factors; (iv) whole-body MRI (WBMRI) allows early detection of tumours in variant carriers and (v) in cancer patients with germline disease-causing \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e variants, radiotherapy, and conventional genotoxic chemotherapy contribute to the development of subsequent primary tumours. It is critical to perform \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e testing before the initiation of treatment in order to avoid in carriers, if possible, radiotherapy and genotoxic chemotherapies. In children, the recommendations are to perform clinical examination and abdominal ultrasound every 6 months, annual WBMRI and brain MRI from the first year of life, if the \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e variant is known to be associated with childhood cancers. In adults, the surveillance should include every year clinical examination, WBMRI, breast MRI in females from 20 until 65 years and brain MRI until 50 years.\u003c/jats:p\u003e",
  "alternative-id": [
    "638"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "11 February 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "28 March 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "8 April 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "26 May 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare that they have no conflict of interest."
    },
    {
      "group": {
        "label": "Disclaimer",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The content of these guidelines represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Frebourg",
      "given": "Thierry",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "name": "The European Reference Network GENTURIS",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Bajalica Lagercrantz",
      "given": "Svetlana",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Oliveira",
      "given": "Carla",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Magenheim",
      "given": "Rita",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-8482-5784",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Evans",
      "given": "D. Gareth",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        5,
        26
      ]
    ],
    "date-time": "2020-05-26T13:02:24Z",
    "timestamp": 1590498144000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        20
      ]
    ],
    "date-time": "2023-05-20T21:01:51Z",
    "timestamp": 1684616511000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        5,
        1
      ]
    ],
    "date-time": "2024-05-01T14:20:44Z",
    "timestamp": 1714573244834
  },
  "is-referenced-by-count": 167,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "10",
  "issued": {
    "date-parts": [
      [
        2020,
        5,
        26
      ]
    ]
  },
  "journal-issue": {
    "issue": "10",
    "published-print": {
      "date-parts": [
        [
          2020,
          10
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            5,
            26
          ]
        ],
        "date-time": "2020-05-26T00:00:00Z",
        "timestamp": 1590451200000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            5,
            26
          ]
        ],
        "date-time": "2020-05-26T00:00:00Z",
        "timestamp": 1590451200000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/s41431-020-0638-4.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0638-4",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0638-4.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1379-1386",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2020,
        5,
        26
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        5,
        26
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2020,
        10
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.7326/0003-4819-71-4-747",
      "author": "FP Li",
      "doi-asserted-by": "crossref",
      "first-page": "747",
      "journal-title": "Ann Intern Med",
      "key": "638_CR1",
      "unstructured": "Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747–52.",
      "volume": "71",
      "year": "1969"
    },
    {
      "DOI": "10.1126/science.1978757",
      "author": "D Malkin",
      "doi-asserted-by": "crossref",
      "first-page": "1233",
      "journal-title": "Science",
      "key": "638_CR2",
      "unstructured": "Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–8.",
      "volume": "250",
      "year": "1990"
    },
    {
      "DOI": "10.1038/348747a0",
      "author": "S Srivastava",
      "doi-asserted-by": "crossref",
      "first-page": "747",
      "journal-title": "Nature",
      "key": "638_CR3",
      "unstructured": "Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–9.",
      "volume": "348",
      "year": "1990"
    },
    {
      "DOI": "10.1200/JCO.2008.16.6959",
      "author": "KD Gonzalez",
      "doi-asserted-by": "crossref",
      "first-page": "1250",
      "journal-title": "J Clin Oncol.",
      "key": "638_CR4",
      "unstructured": "Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–6.",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1136/jmg.2009.073429",
      "author": "MW Ruijs",
      "doi-asserted-by": "crossref",
      "first-page": "421",
      "journal-title": "J Med Genet.",
      "key": "638_CR5",
      "unstructured": "Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47:421–8.",
      "volume": "47",
      "year": "2010"
    },
    {
      "DOI": "10.1200/JCO.2014.59.5728",
      "author": "G Bougeard",
      "doi-asserted-by": "crossref",
      "first-page": "2345",
      "journal-title": "J Clin Oncol.",
      "key": "638_CR6",
      "unstructured": "Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345–52.",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1086/302575",
      "author": "JM Varley",
      "doi-asserted-by": "crossref",
      "first-page": "995",
      "journal-title": "Am J Hum Genet",
      "key": "638_CR7",
      "unstructured": "Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999;65:995–1006.",
      "volume": "65",
      "year": "1999"
    },
    {
      "DOI": "10.1093/jnci/86.22.1707",
      "author": "J Wagner",
      "doi-asserted-by": "crossref",
      "first-page": "1707",
      "journal-title": "J Natl Cancer Inst",
      "key": "638_CR8",
      "unstructured": "Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst. 1994;86:1707–10. 16",
      "volume": "86",
      "year": "1994"
    },
    {
      "DOI": "10.1200/JCO.2013.52.6863",
      "author": "JD Wasserman",
      "doi-asserted-by": "crossref",
      "first-page": "602",
      "journal-title": "J Clin Oncol",
      "key": "638_CR9",
      "unstructured": "Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children’s oncology group study. J Clin Oncol. 2015;33:602–9.",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1200/JCO.2009.26.8169",
      "author": "U Tabori",
      "doi-asserted-by": "crossref",
      "first-page": "1995",
      "journal-title": "J Clin Oncol",
      "key": "638_CR10",
      "unstructured": "Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol. 2010;28:1995–2001.",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1002/cncr.28507",
      "author": "S Hettmer",
      "doi-asserted-by": "crossref",
      "first-page": "1068",
      "journal-title": "Cancer",
      "key": "638_CR11",
      "unstructured": "Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014;120:1068–75.",
      "volume": "120",
      "year": "2014"
    },
    {
      "DOI": "10.1002/humu.23656",
      "author": "C Fortuno",
      "doi-asserted-by": "crossref",
      "first-page": "1764",
      "journal-title": "Hum Mutat.",
      "key": "638_CR12",
      "unstructured": "Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 2018;39:1764–73.",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1136/jmg.2008.058958",
      "author": "KD Gonzalez",
      "doi-asserted-by": "crossref",
      "first-page": "689",
      "journal-title": "J Med Genet.",
      "key": "638_CR13",
      "unstructured": "Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46:689–93.",
      "volume": "46",
      "year": "2009"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104976",
      "author": "M Renaux-Petel",
      "doi-asserted-by": "crossref",
      "first-page": "173",
      "journal-title": "J Med Genet",
      "key": "638_CR14",
      "unstructured": "Renaux-Petel M, Charbonnier F, Théry JC, Fermey P, Lienard G, Bou J, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet. 2018;55:173–80.",
      "volume": "55",
      "year": "2018"
    },
    {
      "DOI": "10.1038/ng.2532",
      "author": "L Holmfeldt",
      "doi-asserted-by": "crossref",
      "first-page": "242",
      "journal-title": "Nat Genet.",
      "key": "638_CR15",
      "unstructured": "Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–52.",
      "volume": "45",
      "year": "2013"
    },
    {
      "DOI": "10.1200/JCO.2017.75.5215",
      "author": "M Qian",
      "doi-asserted-by": "crossref",
      "first-page": "591",
      "journal-title": "J Clin Oncol",
      "key": "638_CR16",
      "unstructured": "Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 Germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36:591–9.",
      "volume": "36",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1470-2045(18)30242-0",
      "author": "SM Waszak",
      "doi-asserted-by": "crossref",
      "first-page": "785",
      "journal-title": "Lancet Oncol.",
      "key": "638_CR17",
      "unstructured": "Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19:785–98.",
      "volume": "19",
      "year": "2018"
    },
    {
      "DOI": "10.1073/pnas.1431692100",
      "author": "S Kato",
      "doi-asserted-by": "crossref",
      "first-page": "8424",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "638_CR18",
      "unstructured": "Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 2003;100:8424–9.",
      "volume": "100",
      "year": "2003"
    },
    {
      "DOI": "10.1093/hmg/ddx106",
      "author": "Y Zerdoumi",
      "doi-asserted-by": "crossref",
      "first-page": "2591",
      "journal-title": "Hum Mol Genet",
      "key": "638_CR19",
      "unstructured": "Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg T, et al. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet. 2017;26:2591–602.",
      "volume": "26",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41588-018-0204-y",
      "author": "AO Giacomelli",
      "doi-asserted-by": "crossref",
      "first-page": "1381",
      "journal-title": "Nat Genet.",
      "key": "638_CR20",
      "unstructured": "Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381–7.",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.molcel.2018.06.012",
      "author": "E Kotler",
      "doi-asserted-by": "crossref",
      "first-page": "178",
      "journal-title": "Mol Cell.",
      "key": "638_CR21",
      "unstructured": "Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell. 2018;71:178–90.",
      "volume": "71",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.stem.2017.07.010",
      "author": "CC Coombs",
      "doi-asserted-by": "crossref",
      "first-page": "374",
      "journal-title": "Cell Stem Cell",
      "key": "638_CR22",
      "unstructured": "Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374–82.e4.",
      "volume": "21",
      "year": "2017"
    },
    {
      "DOI": "10.1002/humu.23653",
      "author": "K Weber-Lassalle",
      "doi-asserted-by": "crossref",
      "first-page": "2040",
      "journal-title": "Hum Mutat.",
      "key": "638_CR23",
      "unstructured": "Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, et al. Diagnosis of Li-Fraumeni syndrome: differentiating TP53 germline mutations from clonal hematopoiesis: results of the observational AGO-TR1 trial. Hum Mutat. 2018;39:2040–6.",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1038/gim.2017.196",
      "author": "JN Weitzel",
      "doi-asserted-by": "crossref",
      "first-page": "809",
      "journal-title": "Genet Med.",
      "key": "638_CR24",
      "unstructured": "Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H, Blazer KR, et al. Somatic TP53 variants frequently confound germ-line testing results. Genet Med. 2018;20:809–16.",
      "volume": "20",
      "year": "2018"
    },
    {
      "DOI": "10.1097/MOH.0000000000000509",
      "author": "S Chen",
      "doi-asserted-by": "crossref",
      "first-page": "235",
      "journal-title": "Curr Opin Hematol",
      "key": "638_CR25",
      "unstructured": "Chen S, Liu Y. p53 involvement in clonal hematopoiesis of indeterminate potential. Curr Opin Hematol. 2019;4:235–40.",
      "volume": "4",
      "year": "2019"
    },
    {
      "DOI": "10.1054/bjoc.2000.1167",
      "author": "A Chompret",
      "doi-asserted-by": "crossref",
      "first-page": "1 932",
      "journal-title": "Br J Cancer",
      "key": "638_CR26",
      "unstructured": "Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1 932–7.",
      "volume": "82",
      "year": "2000"
    },
    {
      "DOI": "10.1002/cncr.30248",
      "author": "PL Mai",
      "doi-asserted-by": "crossref",
      "first-page": "3673",
      "journal-title": "Cancer",
      "key": "638_CR27",
      "unstructured": "Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122:3673–81.",
      "volume": "122",
      "year": "2016"
    },
    {
      "DOI": "10.1097/CCO.0000000000000423",
      "author": "A Amadou",
      "doi-asserted-by": "crossref",
      "first-page": "23",
      "journal-title": "Curr Opin Oncol",
      "key": "638_CR28",
      "unstructured": "Amadou A, Waddington Achatz MI, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30:23–29.",
      "volume": "30",
      "year": "2018"
    },
    {
      "DOI": "10.1002/humu.23673",
      "author": "KC de Andrade",
      "doi-asserted-by": "crossref",
      "first-page": "97",
      "journal-title": "Hum Mutat",
      "key": "638_CR29",
      "unstructured": "de Andrade KC, Frone MN, Wegman-Ostrosky T, Khincha PP, Kim J, Amadou A, et al. Variable population prevalence estimates of germline TP53 variants: a gnomAD-based analysis. Hum Mutat. 2019;40:97–105.",
      "volume": "40",
      "year": "2019"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-19-0728.",
      "doi-asserted-by": "publisher",
      "key": "638_CR30",
      "unstructured": "Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, et al. Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts. Cancer Res. 2019. https://doi.org/10.1158/0008-5472.CAN-19-0728."
    },
    {
      "DOI": "10.1053/j.gastro.2005.10.014",
      "author": "P Wong",
      "doi-asserted-by": "crossref",
      "first-page": "73",
      "journal-title": "Gastroenterology",
      "key": "638_CR31",
      "unstructured": "Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology. 2006;130:73–9.",
      "volume": "130",
      "year": "2006"
    },
    {
      "DOI": "10.1001/jamaoncol.2015.0197",
      "author": "MB Yurgelun",
      "doi-asserted-by": "crossref",
      "first-page": "214",
      "journal-title": "JAMA Oncol",
      "key": "638_CR32",
      "unstructured": "Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, et al. Germline TP53 mutations in patients with early-onset colorectal cancer in the colon cancer family registry. JAMA Oncol. 2015;1:214–21.",
      "volume": "1",
      "year": "2015"
    },
    {
      "DOI": "10.1053/j.gastro.2018.09.036",
      "author": "SP MacFarland",
      "doi-asserted-by": "crossref",
      "first-page": "273",
      "journal-title": "Gastroenterology",
      "key": "638_CR33",
      "unstructured": "MacFarland SP, Zelley K, Long JM, McKenna D, Mamula P, Domchek SM, et al. earlier colorectal cancer screening may be necessary in patients with Li-Fraumeni syndrome. Gastroenterology. 2019;15:273–4.",
      "volume": "15",
      "year": "2019"
    },
    {
      "DOI": "10.1136/jmg.2004.030551",
      "author": "BC Figueiredo",
      "doi-asserted-by": "crossref",
      "first-page": "91",
      "journal-title": "J Med Genet",
      "key": "638_CR34",
      "unstructured": "Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006;43:91–6.",
      "volume": "43",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.canlet.2005.12.039",
      "author": "MI Achatz",
      "doi-asserted-by": "crossref",
      "first-page": "96",
      "journal-title": "Cancer Lett.",
      "key": "638_CR35",
      "unstructured": "Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007;245:96–102.",
      "volume": "245",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.canlet.2007.10.044",
      "author": "EI Palmero",
      "doi-asserted-by": "crossref",
      "first-page": "21",
      "journal-title": "Cancer Lett",
      "key": "638_CR36",
      "unstructured": "Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008;261:21–5.",
      "volume": "261",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.ejca.2018.06.011",
      "author": "E Kasper",
      "doi-asserted-by": "crossref",
      "first-page": "254",
      "journal-title": "Eur J Cancer",
      "key": "638_CR37",
      "unstructured": "Kasper E, Angot E, Colasse E, Nicol L, Sabourin JC, Adriouch S, et al. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer. 2018;101:254–62.",
      "volume": "101",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1470-2045(16)30249-2",
      "author": "A Villani",
      "doi-asserted-by": "crossref",
      "first-page": "1295",
      "journal-title": "Lancet Oncol.",
      "key": "638_CR38",
      "unstructured": "Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17:1295–305.",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-17-0408",
      "author": "CP Kratz",
      "doi-asserted-by": "crossref",
      "first-page": "e38",
      "journal-title": "Clin Cancer Res.",
      "key": "638_CR39",
      "unstructured": "Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2018;23:e38–e45.",
      "volume": "23",
      "year": "2018"
    },
    {
      "DOI": "10.1001/jamaoncol.2017.1968",
      "author": "ML Ballinger",
      "doi-asserted-by": "crossref",
      "first-page": "1634",
      "journal-title": "JAMA Oncol",
      "key": "638_CR40",
      "unstructured": "Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol. 2017;3:1634–9.",
      "volume": "3",
      "year": "2017"
    },
    {
      "DOI": "10.1001/jamaoncol.2017.1358",
      "author": "O Caron",
      "doi-asserted-by": "crossref",
      "first-page": "1736",
      "journal-title": "JAMA Oncol",
      "key": "638_CR41",
      "unstructured": "Caron O, Frebourg T, Benusiglio PR, Foulon S, Brugières L. Lung adenocarcinoma as part of the Li-Fraumeni syndrome spectrum: preliminary data of the LIFSCREEN randomized clinical trial. JAMA Oncol. 2017;3:1736–7.",
      "volume": "3",
      "year": "2017"
    },
    {
      "DOI": "10.1001/jamaoncol.2017.1346",
      "author": "MWG Ruijs",
      "doi-asserted-by": "crossref",
      "first-page": "1733",
      "journal-title": "JAMA Oncol",
      "key": "638_CR42",
      "unstructured": "Ruijs MWG, Loo CE, van Buchem CAJM, Bleiker EMA, Sonke GS. Surveillance of Dutch patients with Li-Fraumeni syndrome: the LiFe-Guard study. JAMA Oncol. 2017;3:1733–4.",
      "volume": "3",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s10689-017-9965-1",
      "author": "S Saya",
      "doi-asserted-by": "crossref",
      "first-page": "433",
      "journal-title": "Fam Cancer",
      "key": "638_CR43",
      "unstructured": "Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, et al. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer. 2017;16:433–40.",
      "volume": "16",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s10689-017-0034-6",
      "author": "J Bojadzieva",
      "doi-asserted-by": "crossref",
      "first-page": "287",
      "journal-title": "Fam Cancer",
      "key": "638_CR44",
      "unstructured": "Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, et al. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer 2018;17:287–94.",
      "volume": "17",
      "year": "2018"
    },
    {
      "DOI": "10.1002/pbc.26822",
      "doi-asserted-by": "publisher",
      "key": "638_CR45",
      "unstructured": "O’Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, et al. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr. Blood Cancer. 2018;65. https://doi.org/10.1002/pbc.26822."
    },
    {
      "DOI": "10.1186/s40644-018-0162-8",
      "author": "D Paixao",
      "doi-asserted-by": "crossref",
      "journal-title": "Cancer Imaging",
      "key": "638_CR46",
      "unstructured": "Paixao D, Guimaraes MD, de Andrade KC, Nobrega AF, Chojniak R, Achatz MI. Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients. Cancer Imaging. 2018;18:27.",
      "volume": "18",
      "year": "2018"
    },
    {
      "DOI": "10.1111/bcp.13718",
      "author": "KA Layne",
      "doi-asserted-by": "crossref",
      "first-page": "2522",
      "journal-title": "Br J Clin Pharm",
      "key": "638_CR47",
      "unstructured": "Layne KA, Dargan PI, JRH Archer, Wood DM. Gadolinium deposition and the potential for toxicological sequelae—a literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharm. 2018;84:2522–34.",
      "volume": "84",
      "year": "2018"
    }
  ],
  "reference-count": 47,
  "references-count": 47,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-020-0638-4"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "28"
}